Related Experiment Video
Updated: Aug 12, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level
J D Forman1, K Meetze, E Pontes
1Department of Radiation Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
The Journal of Urology
|September 25, 1997
Summary
Post-prostatectomy therapeutic radiation is effective for elevated prostate specific antigen (PSA) levels. Patients with lower PSA showed higher disease-free rates, indicating radiation
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Prostate cancer recurrence after prostatectomy can be indicated by rising prostate specific antigen (PSA).
- Adjuvant or salvage radiation therapy is a treatment option for such cases.
- Determining the efficacy of post-prostatectomy radiation for elevated PSA is crucial for patient management.
Purpose of the Study:
- To evaluate the effectiveness of post-prostatectomy therapeutic radiation in patients with elevated PSA.
- To identify prognostic factors influencing outcomes in patients receiving radiation therapy after prostatectomy.
Main Methods:
- A cohort of 47 patients received 66 Gy of therapeutic irradiation to the prostate bed.
- Patients had a postoperative PSA level greater than 0 ng/ml.
- Univariate and multivariate survival analyses were conducted to identify prognostic variables.
Main Results:
- At a median follow-up of 36 months, 83% of patients with PSA ≤ 2 ng/ml had no evidence of disease.
- 33% of patients with PSA > 2 ng/ml had no evidence of disease (p = 0.001).
- Pathological stage and achieving a complete biochemical response (PSA < 0.05 ng/ml) were significant prognostic factors.
Conclusions:
- Post-prostatectomy therapeutic radiation is a highly effective treatment for patients with elevated PSA.
- Overall, 64% of patients remained disease-free at a median follow-up of 36 months.
- Radiation therapy can lead to favorable outcomes in select patients with recurrent prostate cancer.
